Summit Therapeutics PLC (SMMT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has a cash flow conversion efficiency ratio of -0.224x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-92.74 Million) by net assets ($414.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Summit Therapeutics PLC (SMMT) liquidity interval to measure how many days the company can operate on defensive assets alone.
Summit Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Summit Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Summit Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Summit Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Max Healthcare Institute Limited
NSE:MAXHEALTH
|
0.081x |
|
Western Mining Co Ltd
SHG:601168
|
0.053x |
|
Wynn Resorts Limited
NASDAQ:WYNN
|
-0.464x |
|
Westlake Chemical Corporation
NYSE:WLK
|
-0.010x |
|
RAIFFEIS. UNSPON.ADR/1/4
F:RAW0
|
0.025x |
|
Alcoa Corp
NYSE:AA
|
0.040x |
|
Mazagon Dock Shipbuilders Limited
NSE:MAZDOCK
|
0.004x |
|
Absa Group Ltd
JSE:ABG
|
-0.449x |
Annual Cash Flow Conversion Efficiency for Summit Therapeutics PLC (2003–2025)
The table below shows the annual cash flow conversion efficiency of Summit Therapeutics PLC from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see SMMT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $488.98 Million | $-239.67 Million | -0.490x | -34.08% |
| 2024-12-31 | $310.64 Million | $-113.56 Million | -0.366x | +63.00% |
| 2023-12-31 | $61.48 Million | $-60.74 Million | -0.988x | -200.93% |
| 2022-12-31 | $103.25 Million | $-33.90 Million | -0.328x | +62.33% |
| 2021-12-31 | $61.74 Million | $-53.81 Million | -0.872x | -43.93% |
| 2020-12-31 | $58.36 Million | $-35.34 Million | -0.606x | -38.80% |
| 2019-12-31 | $61.12 Million | $-26.66 Million | -0.436x | +30.67% |
| 2018-12-31 | $55.79 Million | $-35.11 Million | -0.629x | +57.26% |
| 2017-12-31 | $13.98 Million | $-20.58 Million | -1.472x | +57.64% |
| 2016-12-31 | $-4.37 Million | $15.18 Million | -3.476x | -327.51% |
| 2015-12-31 | $30.10 Million | $-24.47 Million | -0.813x | +4.27% |
| 2014-12-31 | $19.53 Million | $-16.59 Million | -0.849x | +31.09% |
| 2013-12-31 | $7.85 Million | $-9.68 Million | -1.232x | -10.25% |
| 2012-12-31 | $4.50 Million | $-5.03 Million | -1.118x | -11.09% |
| 2011-12-31 | $3.78 Million | $-3.80 Million | -1.006x | -35.07% |
| 2010-12-31 | $5.82 Million | $-4.34 Million | -0.745x | -272.40% |
| 2009-12-31 | $13.22 Million | $-2.65 Million | -0.200x | +83.25% |
| 2008-12-31 | $12.33 Million | $-14.72 Million | -1.194x | -300.46% |
| 2007-12-31 | $54.08 Million | $-16.13 Million | -0.298x | -100.73% |
| 2006-12-31 | $40.11 Million | $-5.96 Million | -0.149x | -272.67% |
| 2005-12-31 | $23.38 Million | $-931.84K | -0.040x | -3655.45% |
| 2004-12-31 | $26.53 Million | $29.74K | 0.001x | +100.25% |
| 2003-12-31 | $142.31K | $-64.97K | -0.457x | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cance… Read more